Abstract
Evaluation of the effectiveness of small molecule radiation protectors and mitigators requires in vitro assays for clonogenic survival and analyses of drug effects on apoptosis and DNA damage repair. Application of novel mitigators for potential use in normal tissue protection during clinical radiation therapy and radiation counter terrorism mandates animal testing which, in the LD 50/30 assay for the effects of TBI on the hematopoietic syndrome, involves significant expense. We tested the hypothesis that early evaluation of candidate drugs in human cord blood clonogenic assay could potentially identify drugs which, while effective in the murine system, might be ineffective in humans.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
